• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• cemiplimab
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• Immune checkpoint association
• durvalumab plus tremelimumab
• nivolumab plus ipilimumab
• pembrolizumab plus ipilimumab

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs gemcitabine plus platin
• vs paclitaxel plus carboplatin
• vs pemetrexed plus platin
• vs Standard of Care (SoC)
• vs immune chekpoint inhibitors
• vs anti-PD-(L)1
• vs pembrolizumab based treatment
• vs pembrolizumab alone
• vs pembrolizumab plus placebo
• vs pembrolizumab plus SoC

  Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only